"Novartis’ oral remibrutinib demonstrated significant reductions in relapse rates compared to teriflunomide in pivotal Phase 3 trials for relapsing multiple sclerosis, offering a promising new oral treatment option with no observed liver safety concerns, a critical distinction for its drug class."
Novartis has unveiled compelling topline results from two identical Phase 3 clinical trials, REMODEL-1 and REMODEL-2, showcasing the efficacy of its oral Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib. In adults diagnosed with relapsing multiple sclerosis (MS), the investigational drug significantly outperformed teriflunomide, a well-established oral therapy, in reducing annualized relapse rates. Crucially, remibrutinib presented a clean safety profile, notably avoiding the liver safety signals that have historically complicated the development of other BTK inhibitors. These findings, announced on September 1, 2026, represent a significant step forward in the search for highly effective oral treatments for MS, a condition affecting millions worldwide.
The REMODEL-1 and REMODEL-2 studies, which together enrolled approximately 2,000 patients globally, were designed as identical, multicenter, randomized, double-blind trials. The primary objective was to assess remibrutinib’s efficacy against teriflunomide in reducing the annualized relapse rate (ARR) in adults with relapsing MS who exhibited recent disease activity and had an Expanded Disability Status Scale (EDSS) score ranging from 0.0 to 5.5. Patients were randomized in a one-to-one ratio, with a double-blind treatment period lasting up to 30 months, followed by an optional open-label extension of up to five years.
Both trials successfully met their primary endpoint by demonstrating a statistically significant reduction in ARR for patients treated with remibrutinib compared to those receiving teriflunomide. Furthermore, remibrutinib showed superiority across all key secondary endpoints within each trial, including significant reductions in the formation of new or enlarging MRI lesions. These lesions are a critical indicator of underlying disease activity in MS.
However, the initial announcement of these "topline results" lacked specific numerical data. Novartis has yet to release the precise relapse rates, the magnitude of the difference between the treatment arms, detailed MRI lesion counts, or a comprehensive breakdown of adverse events. This granular data is anticipated for a late-breaking presentation scheduled for October, where independent assessment and a deeper understanding of remibrutinib’s performance will be possible.
The distinction between a topline announcement and a full data release is crucial for interpreting clinical trial outcomes. A topline report confirms whether a trial met its predefined endpoints but does not provide the quantitative evidence needed to fully assess the clinical benefit or the associated risks. In the case of remibrutinib, the comparator drug, teriflunomide (marketed as Aubagio and now available generically), is considered a moderately effective oral therapy. While statistically outperforming teriflunomide is a meaningful achievement, it does not definitively position remibrutinib relative to the higher efficacy of infused anti-CD20 antibodies, which are often the first-line treatment choice for patients with highly active MS.
Novartis did report positive trends concerning disability progression. In a preplanned combined analysis of both trials, remibrutinib showed a positive trend for three-month confirmed disability progression and achieved nominal statistical significance for the six-month measure. However, the company did not disclose the specific rates associated with these findings. Nominal significance in a pooled analysis is a less stringent statistical claim than meeting an endpoint within a single trial, underscoring the need for the upcoming detailed data release.
Shreeram Aradhye, Chief Medical Officer at Novartis, emphasized the ongoing need for oral therapies that can provide robust relapse prevention while simultaneously slowing disability progression and maintaining a favorable safety profile. This statement highlights the unmet need that remibrutinib aims to address within the MS treatment landscape.
A significant point of discussion surrounding BTK inhibitors in MS has been their potential for liver enzyme elevations. This class of drugs targets Bruton’s tyrosine kinase, an enzyme crucial for the development and function of B cells and certain innate immune cells. While this mechanism offers a novel approach to MS management, liver toxicity has been a recurring concern in the development of other BTK inhibitors. Novartis’ report of no liver safety signal, including the absence of cases meeting Hy’s Law criteria (a regulatory benchmark for potential liver injury), is a particularly encouraging development. This favorable safety profile is further supported by a broader development program involving over 4,500 trial participants across various conditions, where safety data has been consistently monitored.
Remibrutinib is not a new entity; it received FDA approval as Rhapsido in September 2025, and European Union approval in April 2026, for the treatment of chronic spontaneous urticaria (CSU) at a lower dose of 25 mg. This prior regulatory clearance and exposure in a different patient population provide some real-world safety context. However, the treatment of MS typically involves longer durations, potentially higher doses, and a different risk-benefit calculus compared to CSU.
The mechanism of action of BTK inhibitors like remibrutinib differentiates them from existing MS therapies. Unlike infused anti-CD20 antibodies that deplete B cells, BTK inhibitors modulate B cell and innate immune cell signaling. This targeted approach is of significant interest as it may offer a less immunosuppressive treatment option, potentially leading to a reduced risk of infections over the long term. However, definitive conclusions regarding infection rates and the long-term impact of this mechanism on patient immunity cannot be drawn from topline data alone. It is important to note that the data presented is company-reported and has not yet undergone independent peer review or external scrutiny.
It is imperative to stress that remibrutinib is not currently approved for multiple sclerosis in any jurisdiction. Consequently, it cannot be prescribed for MS, and patients should not consider altering their current treatment plans based on this announcement. Individuals currently taking teriflunomide, fumarates, or sphingosine-1-phosphate (S1P) modulators should continue their prescribed regimens without interruption. Abruptly discontinuing disease-modifying therapies for MS, especially without medical supervision, carries significant risks, including the potential for rebound disease activity, a phenomenon observed with certain drug classes.
The patient population that will ultimately benefit most from remibrutinib, should it gain approval for MS, includes those who desire an oral treatment option but find existing oral therapies insufficient for disease control, as well as individuals who wish to avoid regular intravenous infusions. An oral therapy that can achieve efficacy levels comparable to infused treatments would effectively fill a recognized gap in the management of relapsing MS. The forthcoming full data will be critical in substantiating this claim.
Questions surrounding cost and patient access remain unresolved and will persist until regulatory approval. The pricing of Rhapsido for urticaria is not necessarily indicative of potential MS pricing. Furthermore, coverage for MS disease-modifying therapies typically involves complex processes such as prior authorization, specialty pharmacy dispensing, and step-therapy requirements, which vary significantly by insurance plan. Patients facing access challenges with their current treatments are encouraged to discuss potential manufacturer assistance programs and appeal options with their neurology team.
The full dataset from the REMODEL trials is slated for presentation as a late-breaking abstract at the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). This prestigious congress is scheduled to take place in Toronto from October 21 to 23, 2026. Following this scientific presentation, an investor call is anticipated. This is when detailed information on relapse rates, effect sizes, lesion data, and comprehensive adverse event tables are expected to become publicly available for independent evaluation.
Novartis has indicated its intention to seek global regulatory approval for remibrutinib for MS. However, a specific filing date has not yet been announced. Regulatory review processes typically span several months to over a year from the date of submission, depending on the complexity of the data and the specific requirements of each regulatory agency.
Beyond relapsing MS, Novartis is actively investigating remibrutinib in other indications. The REMASTER trial is a Phase 3 study assessing its efficacy in secondary progressive MS, a more challenging form of the disease with fewer treatment options. Additionally, remibrutinib is being explored in trials for hidradenitis suppurativa and food allergies, including a specific trial in adults with peanut allergy. Positive results in progressive MS, if achieved, would be particularly impactful for a patient population with significant unmet needs.
For patients and clinicians, three key aspects will warrant close attention in the coming months. Firstly, the precise annualized relapse rate figures to be presented in October will determine the magnitude of remibrutinib’s benefit – whether it is modest or substantial. Secondly, the complete safety dataset, with a particular focus on infection rates and any emergent liver enzyme findings across the entire exposure period, will be crucial for understanding the long-term safety profile. Finally, the regulatory agencies’ assessment of the pooled disability analysis versus requiring single-trial evidence will be a critical determinant in the approval process. Until these crucial data points are thoroughly evaluated, the current announcement represents a positive signal from a company press release rather than a basis for immediate treatment decisions.
